--- title: "VolitionRx gets Lind waiver for ATM sales above $10 million" url: "https://aibio.space/news/volitionrx-gets-lind-waiver-atm-sales-above-10-million/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-09-02" section: "Debt Financing" tickers: "NYSE:VNRX" source: "https://www.sec.gov/Archives/edgar/data/93314/000147793226005359/vnrx_8k.htm" summary: "Lind Global Asset Management XII waived defaults tied to at-the-market sales above the $10 million annual cap on notes issued in 2025 and 2026." --- By the aibio.space news desk. Sources - [VOLITIONRX LTD 8-K (2026-09-02)](https://www.sec.gov/Archives/edgar/data/93314/000147793226005359/vnrx_8k.htm) - [VOLITIONRX LTD financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/93314/000147793226001832/) [VNRX](https://aibio.space/companies/volitionrx/) 2026-09-02 # VolitionRx gets Lind waiver for ATM sales above $10 million Tickers [VNRX](https://aibio.space/companies/volitionrx/) Lind Global Asset Management XII waived defaults tied to at-the-market sales above the $10 million annual cap on notes issued in 2025 and 2026. ## Key facts - **Company**: VOLITIONRX LTD (NYSE: VNRX) - **News type**: Debt Financing - **Primary source**: [VOLITIONRX LTD 8-K (2026-09-02)](https://www.sec.gov/Archives/edgar/data/93314/000147793226005359/vnrx_8k.htm) *Trading screens with price charts. CC0, via rawpixel. The picture shows the field, not the companies named.* VolitionRx Limited entered into a waiver and consent with Lind Global Asset Management XII LLC on September 2, 2026, according to a Form 8-K filed the same day. Lind is the lender under two senior secured convertible promissory notes and related warrants, issued under a securities purchase agreement dated May 15, 2025, as amended and restated on January 7, 2026. The filing names no placement agent or advisor for the notes or the waiver. ## The notes and warrants The company issued a $7,500,000 note to Lind on May 15, 2025, with a warrant exercisable for 651,042 shares of common stock. On January 7, 2026 it issued a second note of $2,400,000, with a warrant exercisable for 350,018 shares. Both notes are convertible into common stock. The purchase agreement lets the company sell up to $10 million under its at-the-market agreement in each calendar year as permitted ATM sales. Sales above that amount would otherwise be prohibited transactions under the agreement and the notes, and they can trigger remedies. ## What the waiver does Under the waiver, Lind consented to all ATM sales, including those above $10 million in a calendar year, as permitted sales and not prohibited transactions. Lind also waived remedies tied to past or future ATM sales, including the right to declare amounts due, demand immediate payment, accelerate obligations or foreclose on collateral, to the extent those remedies are triggered by such sales. It also waived existing or future events of default for covenant breaches arising from ATM sales. The remedies waived sit in Sections 5.9 and 7.3 of the purchase agreement and Sections 4.1(f) and 2.2 of each note. The waiver is filed as Exhibit 10.1 to the 8-K, which Chief Executive Officer and President Cameron Reynolds signed. The waiver covers one failure in particular. Lind waived any breach arising from the company's failure to give timely notice of above-cap ATM sales before the waiver date, so that failure carries no remedy under the waiver. Lind also waived any adjustment to the conversion price and the warrant exercise price for ATM sales after August 28, 2026. Those prices had already been adjusted for sales through that date under the existing terms. For the company, the waiver stops further price resets from ATM sales. The 8-K does not give the adjusted prices, and it describes no new funding from the waiver. ## The company and its finances VolitionRx's common stock trades as VNRX on NYSE American. The financial figures show a shrinking loss. Revenue was $1.7 million in 2025 and $1.2 million in 2024. Research and development expense fell to $10.1 million in 2025 from $14.4 million in 2024. The net loss narrowed to $23.4 million in 2025 from $27.0 million in 2024, and cash used in operations fell to $19.7 million from $25.9 million. The cash position is thin. Year-end cash was $3.3 million in 2024 and $1.1 million in 2025. It rose to $2.8 million at June 30, 2026. The 8-K does not say how much of that increase came from ATM sales, and the waiver is about exactly those sales. The waiver lets the company keep selling stock above the cap under the at-the-market agreement without triggering the Lind remedies. The 8-K does not say how much the company plans to raise under the program, and it describes no other financing. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story VNRX VOLITIONRX LTD NYSE ยท United States Open the starter desk ## More in Debt Financing Debt Financing ### [Pelthos amends Horizon venture loan, funds Loans E to H and adds Loans I and J](https://aibio.space/news/pelthos-amends-horizon-venture-loan-funds-loans-e-h-adds-loans/) Oct 30, 2026 Debt Financing ### [Repligen announces $1.0 billion private convertible notes transaction](https://aibio.space/news/repligen-announces-1-0-billion-private-convertible-notes-transaction/) Oct 30, 2026 Debt Financing ### [FOXO to buy Ludwig Enterprises preferred stock with majority voting power](https://aibio.space/news/foxo-buy-ludwig-enterprises-preferred-stock-majority-voting-power/) Oct 29, 2026 --- Source page: https://aibio.space/news/volitionrx-gets-lind-waiver-atm-sales-above-10-million/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "VolitionRx gets Lind waiver for ATM sales above $10 million", 2026-09-02, https://aibio.space/news/volitionrx-gets-lind-waiver-atm-sales-above-10-million/